CL2019003743A1 - Formas de dosificación oral y de liberación controlada gastrorresistentes. - Google Patents

Formas de dosificación oral y de liberación controlada gastrorresistentes.

Info

Publication number
CL2019003743A1
CL2019003743A1 CL2019003743A CL2019003743A CL2019003743A1 CL 2019003743 A1 CL2019003743 A1 CL 2019003743A1 CL 2019003743 A CL2019003743 A CL 2019003743A CL 2019003743 A CL2019003743 A CL 2019003743A CL 2019003743 A1 CL2019003743 A1 CL 2019003743A1
Authority
CL
Chile
Prior art keywords
dosage forms
controlled release
gastro
subject
oral dosage
Prior art date
Application number
CL2019003743A
Other languages
English (en)
Spanish (es)
Inventor
Nadine Noel
Sandra Werner
Emmanuelle Georgi
Jay Saoud
Remy Luthringer
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62904624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019003743(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of CL2019003743A1 publication Critical patent/CL2019003743A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2019003743A 2017-06-21 2019-12-18 Formas de dosificación oral y de liberación controlada gastrorresistentes. CL2019003743A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762523204P 2017-06-21 2017-06-21

Publications (1)

Publication Number Publication Date
CL2019003743A1 true CL2019003743A1 (es) 2020-07-03

Family

ID=62904624

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003743A CL2019003743A1 (es) 2017-06-21 2019-12-18 Formas de dosificación oral y de liberación controlada gastrorresistentes.

Country Status (15)

Country Link
US (3) US11464744B2 (enExample)
EP (1) EP3641732A1 (enExample)
JP (3) JP2020525436A (enExample)
CN (1) CN111511353A (enExample)
AU (2) AU2018290287B2 (enExample)
BR (1) BR112019027398A2 (enExample)
CA (1) CA3067031A1 (enExample)
CL (1) CL2019003743A1 (enExample)
CO (1) CO2019014496A2 (enExample)
IL (3) IL319156A (enExample)
MX (1) MX2023002994A (enExample)
PE (1) PE20200732A1 (enExample)
UA (1) UA127349C2 (enExample)
WO (1) WO2018237207A1 (enExample)
ZA (1) ZA202409847B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2968977A1 (en) 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
EP3641732A1 (en) 2017-06-21 2020-04-29 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
WO2020041504A1 (en) 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
IT201800011125A1 (it) * 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico
CA3243767A1 (en) 2022-02-14 2023-08-17 Minerva Neurosciences, Inc. USE OF ROLUPERIDONE IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325063B1 (en) 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
ZA908641B (en) 1989-10-27 1992-06-24 Du Pont (n-phthalimidoalkyl)piperidines
NZ251610A (en) 1992-04-23 1996-02-27 Merrell Dow Pharma 4-imidomethyl-1-(2-phenyl-2-oxoethyl)piperidine derivatives and pharmaceutical compositions
PT1260512E (pt) 2000-02-29 2007-10-10 Mitsubishi Pharma Corp ''novos derivados de amida cíclicos''
WO2002026214A1 (en) 2000-09-29 2002-04-04 Solvay Pharmaceuticals B.V. Ion-strength independent sustained release pharmaceutical formulation
US20050095292A1 (en) 2003-10-29 2005-05-05 Wyeth Sustained release pharmaceutical compositions
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
DOP2006000125A (es) 2005-06-06 2006-12-31 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia
JP2009525979A (ja) 2006-02-07 2009-07-16 田辺三菱製薬株式会社 ４−アシルアミノピリジン誘導体を介した神経新生
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
JP2008273954A (ja) 2007-03-30 2008-11-13 Mitsubishi Tanabe Pharma Corp うつ病の予防及び／又は治療剤
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP2246331A1 (en) 2009-04-24 2010-11-03 Westfälische Wilhelms-Universität Münster NR2B-selective NMDA-receptor antagonists
JP5640079B2 (ja) * 2009-05-18 2014-12-10 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 油滴含有組成物
UY33455A (es) 2010-06-16 2012-01-31 Teijin Pharma Ltd Tableta con núcleo recubierto de liberación controlada
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
EP3335731B1 (en) 2010-07-20 2024-09-04 Minerva Neurosciences, Inc. Use of cyclic amide derivatives to treat sleep disorders
EP4070794A3 (en) 2010-07-20 2023-01-18 Minerva Neurosciences, Inc. Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders
US20120040008A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
EP2685966A1 (en) 2011-03-17 2014-01-22 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
CA2845228C (en) * 2011-08-16 2021-08-10 Baker Idi Heart & Diabetes Institute Holdings Limited Oral controlled-release formulation of 5-(pyridinyl)-2(1h)-pyridinone compounds
BR112015023124A2 (pt) * 2013-03-14 2017-07-18 Therabiome Llc liberação de organismos probióticos e/ou agentes terapêuticos almejada para o trato gastrintestinal
CN104586771B (zh) * 2013-10-30 2018-01-16 广州朗圣药业有限公司 一种盐酸坦洛新缓释微丸制剂
MX2016014192A (es) 2014-04-30 2017-05-01 Incyte Corp Procesos para preparar un inhibidor de cinasas de janus 1 (jak1) y nuevas formas de este.
EP3144308B1 (en) 2014-05-16 2020-06-24 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
RU2697851C2 (ru) * 2014-08-13 2019-08-21 Седарс-Синаи Медикал Сентер Антиметаногенные композиции и их применение
CA2968977A1 (en) 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
WO2017066134A1 (en) * 2015-10-16 2017-04-20 Merck Sharp & Dohme Corp. Processes for preparing formulations for gastrointestinal-targeted therapies
SG11201810358YA (en) 2016-05-25 2018-12-28 Mitsubishi Tanabe Pharma Corp Compositions and methods for treating negative symptoms in non-schizophrenic patients
EP3641732A1 (en) 2017-06-21 2020-04-29 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
WO2020041504A1 (en) 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
US12441701B2 (en) 2019-06-28 2025-10-14 Tapi Czech Industries S.R.O. Solid state forms of roluperidone and salts thereof
CA3243767A1 (en) 2022-02-14 2023-08-17 Minerva Neurosciences, Inc. USE OF ROLUPERIDONE IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA

Also Published As

Publication number Publication date
JP2025134828A (ja) 2025-09-17
IL271606B1 (en) 2024-01-01
WO2018237207A1 (en) 2018-12-27
IL271606B2 (en) 2024-05-01
UA127349C2 (uk) 2023-07-26
AU2018290287A1 (en) 2020-01-16
CO2019014496A2 (es) 2020-04-01
JP2023175778A (ja) 2023-12-12
IL319156A (en) 2025-04-01
EP3641732A1 (en) 2020-04-29
IL308650B1 (en) 2025-04-01
US12048768B2 (en) 2024-07-30
RU2020102015A (ru) 2021-07-21
US20250009665A1 (en) 2025-01-09
BR112019027398A2 (pt) 2020-07-07
AU2018290287B2 (en) 2024-06-13
CN111511353A (zh) 2020-08-07
US11464744B2 (en) 2022-10-11
US20220401368A1 (en) 2022-12-22
MX2023002994A (es) 2023-09-15
RU2020102015A3 (enExample) 2021-10-04
AU2024219717A1 (en) 2024-10-03
IL308650A (en) 2024-01-01
ZA202409847B (en) 2025-09-25
IL308650B2 (en) 2025-08-01
CA3067031A1 (en) 2018-12-27
PE20200732A1 (es) 2020-07-23
JP2020525436A (ja) 2020-08-27
IL271606A (en) 2020-02-27
US20190038561A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
CL2019003743A1 (es) Formas de dosificación oral y de liberación controlada gastrorresistentes.
MX2015015228A (es) Sobetirome en el tratamiento de enfermedades de mielinizacion.
MX2021005561A (es) Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco.
MX2019007474A (es) Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
MX2015011473A (es) Compuesto de fosforamidato de nucleosido novedoso y su uso.
MX385678B (es) Gamma-carbolinas heterocíclicas fusionadas sustituidas, composiciones farmacéuticas y métodos de uso.
MX2018012379A (es) Degradadores de proteinas de bromodominio y dominioextraterminal (bet).
MX386547B (es) Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
MX2017002656A (es) Compuestos que inhiben la proteína mcl-1.
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
GT201500086A (es) Análogos de 2'-cloro nucleósido para infección por vhc
MX2017003819A (es) Macrociclos peptidomimeticos y formulaciones de los mismos.
CL2015001923A1 (es) Uso de crenolanib para el tratamiento de trastornos proliferativos que tiene flt3 mutado
AR100006A1 (es) Derivados de tubulisina
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CL2017001904A1 (es) Composición para el tratamiento de enfermedad veno-oclusiva hepática.
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
NI201800071A (es) Compuestos de isoindol
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2015002466A1 (es) Formulaciones de compuestos orgánicos